DECRYPTING THE OLIGO-BENZAMIDE PLATFORM

Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions.  Herein, the design of oligo-benzamides, efficient synthetic routes and preclinical studies showing their activity are detailed. Etira’s therapeutic compounds are based on the oligo-benzamide platform, including ERX-315 which is slated to start clinical trials following HREC approval.

The manuscript can be accessed at  https://doi.org/10.1016/bs.mie.2024.04.022